Neurological Tumor Syndromes: Symptom Patterns by Location

Brain and spinal cord tumors produce distinct symptom constellations—often called "syndromes"—determined by their anatomic location, growth rate, and mass effect on surrounding structures.

Supratentorial (Cerebral Hemispheres)

• Frontal lobe: Personality changes, executive dysfunction, hemiparesis, Broca's aphasia (if dominant hemisphere), seizures.
• Temporal lobe: Memory impairment, complex partial seizures, Wernicke's aphasia (dominant), visual field cuts.
• Parietal lobe: Sensory loss, neglect syndrome (non-dominant), Gerstmann syndrome (dominant), apraxia.
• Occipital lobe: Homonymous hemianopsia, visual hallucinations, alexia.

Infratentorial (Posterior Fossa)

• Cerebellum: Ataxia, dysmetria, nystagmus, vomiting, obstructive hydrocephalus.
• Brainstem: Cranial nerve palsies, long tract signs, respiratory/cardiac center compromise, "locked-in" syndrome.

Spinal Cord

• Extramedullary (meningioma, schwannoma): Radicular pain progressing to myelopathy with upper motor neuron signs below the lesion.
• Intramedullary (ependymoma, astrocytoma): Central cord syndrome (cape-like sensory loss), syrinx formation.

General Signs of Raised Intracranial Pressure (ICP)

• Headache (worse in morning, with Valsalva), nausea/vomiting, papilledema, Cushing's triad (hypertension, bradycardia, irregular respirations).
• Seizures (occur in 30–50% of brain tumor patients).

Diagnostic Pathway

1. Neurologic exam to localize the lesion.
2. MRI with contrast (gold standard).
3. CT if MRI contraindicated or for bone detail.
4. Biopsy or resection for histologic diagnosis.
5. Molecular profiling to guide targeted therapy.

Treatment Modalities

Options include maximal safe surgical resection, radiation (fractionated or stereotactic radiosurgery), chemotherapy (temozolomide, PCV), targeted agents (bevacizumab, tumor-treating fields), and clinical trials. Multidisciplinary neuro-oncology board review is standard.